Search results for "C2"

showing 10 items of 879 documents

Anticoagulation with Factor Xa Inhibitors Is Associated with Improved Overall Response and Progression-Free Survival in Patients with Metastatic Mali…

2021

Immune checkpoint inhibitors (ICI) significantly improved the prognosis of advanced melanoma patients. However, many patients do not derive long-term benefit from ICI therapy due to primary and acquired resistance. In this regard, it has been shown that coagulation factors contribute to cancer immune evasion and might therefore promote resistance to ICI. In particular, recent observations in murine systems demonstrated that myeloid-derived factor Xa (FXa) impedes anti-tumor immunity in the tumor microenvironment and that the oral FXa inhibitor (FXa-i) rivaroxaban synergizes with ICI. The synergistic effect of FXa inhibitors with clinical ICI therapy is unknown. We performed a retrospective …

Oncologyadvanced melanomaCancer Researchmedicine.medical_specialtymedicine.drug_mechanism_of_actionmedicine.medical_treatmentFactor Xa Inhibitorfactor Xa inhibitorsanti-tumor immunityArticleimmune checkpoint inhibitorsInternal medicinemedicineProgression-free survivalanticoagulationRC254-282thromboembolic eventsRivaroxabanbusiness.industryNeoplasms. Tumors. Oncology. Including cancer and carcinogensCancerRetrospective cohort studyImmunotherapymedicine.diseaseOncologyConcomitantimmunotherapythromboprophylaxisbusinesshormones hormone substitutes and hormone antagonistsmedicine.drugCohort studyCancers
researchProduct

PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the r…

2021

Background: The evolution of therapeutic landscape of human epidermal growth factor receptor-2 (HER2)-positive breast cancer (BC) has led to an unprecedented outcome improvement, even if the optimal sequence strategy is still debated. To address this issue and to provide a picture of the advancement of anti-HER2 treatments, we performed a large, multicenter, retrospective study of HER2-positive BC patients. Methods: The observational PANHER study included 1,328 HER2-positive advanced BC patients treated with HER2 blocking agents since June 2000 throughout July 2020. Endpoints of efficacy were progression-free survival (PFS) and overall survival (OS). Results: Patients who received a first-l…

Oncologymedicine.medical_specialtyAdvanced breastT-DM1Treatment outcomeLapatinibBreast cancerpertuzumabInternal medicineMedicinelapatinibRC254-282advanced breast cancerbusiness.industryHuman epidermal growth factoradvanced breast cancer; HER2-positive; lapatinib; pertuzumab; sequence; T-DM1Neoplasms. Tumors. Oncology. Including cancer and carcinogensCancersequencemedicine.diseaseHER2-positiveOncologyObservational studyPertuzumabbusinessmedicine.drug
researchProduct

The prognostic value of four interleukin-1 gene polymorphisms in caucasian women with breast cancer – a multicenter study

2009

Abstract Background The proinflammatory cytokine interleukin-1 (IL-1) is known to play an important role in the carcinogenesis of breast cancer. Although IL-1 gene polymorphisms were reported to be associated with increased risk of breast cancer, their influence on survival of Caucasian breast cancer patients remains to be shown. Methods We studied the influence of four common gene polymorphisms (IL1A -889C/T, IL1B -511C/T, IL1B +3953E1/E2, and IL1RN long/2) of the IL-1 family on survival in 262 Caucasian patients with breast cancer by univariate and multivariate survival analysis. The combined effect of the four gene polymorphisms on overall survival was studied by haplotype analysis. Resu…

Oncologymedicine.medical_specialtyCancer ResearchBreast Neoplasmsmedicine.disease_causelcsh:RC254-282Disease-Free SurvivalWhite PeopleBreast cancerInternal medicineGeneticsMedicineHumansAlleleAllelesPolymorphism Geneticbusiness.industryHaplotypeCancerOdds ratioMiddle Agedmedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensInterleukin 1 Receptor Antagonist ProteinIL1AOncologyImmunologyFemaleGene polymorphismbusinessCarcinogenesisInterleukin-1Research ArticleBMC Cancer
researchProduct

Detection methods predict differences in biology and survival in breast cancer patients

2012

Abstract Background The aim of this study was to measure the biological characteristics involved in tumorigenesis and the progression of breast cancer in symptomatic and screen-detected carcinomas to identify possible differences. Methods For this purpose, we evaluated clinical-pathological parameters and proliferative and apoptotic activities in a series of 130 symptomatic and 161 screen-detected tumors. Results After adjustment for the smaller size of the screen-detected carcinomas compared with symptomatic cancers, those detected in the screening program presented longer disease-free survival (RR = 0.43, CI = 0.19-0.96) and had high estrogen and progesterone receptor concentrations more …

Oncologymedicine.medical_specialtyCancer ResearchSurvivalProliferationBreast NeoplasmsApoptosisKaplan-Meier Estimatemedicine.disease_causelcsh:RC254-282Breast cancerBreast cancerSurgical oncologyInternal medicineDetection methodsmedicineGeneticsHumansMammographyEarly Detection of CancerProportional Hazards Modelsmedicine.diagnostic_testbusiness.industryProportional hazards modelDisease progressionCase-control studyMiddle Agedlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensPrognosismedicine.diseaseImmunohistochemistryOncologyCase-Control StudiesDisease ProgressionImmunohistochemistryFemalebusinessCarcinogenesisMammographyResearch Article
researchProduct

Prognostic value of Thyroid Transcription Factor-1 expression in lung adenocarcinoma in patients treated with anti PD-1/PD-L1.

2021

ABSTRACT Anti-PD1/PD-L1-directed immune checkpoint inhibitors are game changers in advanced non-small-cell lung cancer, but biomarkers are lacking. The aim of our study was to find clinically relevant biomarkers of the efficacy of ICI in non-squamous NSCLC. We conducted a retrospective study of patients receiving ICI for advanced non squamous NSCLC in two cohorts. For a subset of patients, RNAseq data were generated on tumor biopsy taken before ICI. The primary end point was progression-free survival under ICI. Secondary end point was overall survival from ICI initiation. In the cohort, we studied 231 patients. Clinico-pathological characteristics included KRAS mutant status (n = 88), TTF1-…

Oncologymedicine.medical_specialtyLIPI scoreLung Neoplasmsmedicine.medical_treatmentImmunologyThyroid Nuclear Factor 1Adenocarcinoma of Lungmedicine.disease_causeTTF1Internal medicinePD-L1Carcinoma Non-Small-Cell LungmedicineClinical endpointKRASImmunology and AllergyHumansLung cancerImmune Checkpoint InhibitorsRC254-282Retrospective StudiesOriginal Researchbiologybusiness.industryNeoplasms. Tumors. Oncology. Including cancer and carcinogensprognostic factorsRetrospective cohort studyImmunotherapyRC581-607medicine.diseasePrognosisOncologyCohortbiology.proteinAdenocarcinomaKRASimmunotherapyImmunologic diseases. AllergybusinessAdenocarcinoma lung cancerBiomarkersResearch ArticleOncoimmunology
researchProduct

GASTRIC METASTASES ORIGINATING FROM OCCULT BREAST LOBULAR CARCINOMA: DIAGNOSTIC AND THERAPEUTIC PROBLEMS

2008

Abstract Background Breast cancer is the most frequent malignant tumour to metastasize into the gastrointestinal tract in female and is second only to malignant melanoma. Nevertheless gastrointestinal metastases arising from breast cancer are quite rare. The upper gastrointestinal tract is more frequently involved and lobular infiltrating carcinoma has a greater predilection compared to the ductal type. Case presentation The authors describe the case of a 70 years old woman with a preoperative diagnosis of gastric undifferentiated medullary – type carcinoma, which was the first manifestation of an occult breast carcinoma. The primary site of carcinoma was identified with the use of a panel …

Oncologymedicine.medical_specialtyLobular carcinomalcsh:SurgeryBreast NeoplasmsCase Reportlcsh:RC254-282Fatal OutcomeBreast cancerStomach NeoplasmsSurgical oncologyInternal medicinemedicineCarcinomaHumansBREAST CANCER - GASTRIC METASTASESAgedbusiness.industryMelanomaCancerlcsh:RD1-811lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseOccultCarcinoma LobularSettore MED/18 - Chirurgia GeneraleOncologyFemaleSurgeryBreast carcinomabusiness
researchProduct

Analysis of systemic inflammatory biomarkers in neuroendocrine carcinomas of the lung: prognostic and predictive significance of NLR, LDH, ALI, and L…

2020

Background: Lung neuroendocrine carcinoma (NEC) is characterized by aggressive clinical behavior and lack of treatment advances. We evaluate the prognostic and the predictive roles of systemic inflammatory biomarkers in patient circulating blood: neutrophil–lymphocyte ratio (NLR), lactate dehydrogenase (LDH), advanced lung cancer inflammation index (ALI), and the Lung Immune Prognostic Index (LIPI) score. Methods: A total of 120 patients with small-cell lung cancer (SCLC) ( n = 110) and large cell neuroendocrine carcinoma (LCNEC) ( n = 10) were enrolled. Overall survival (OS) was evaluated by Kaplan–Meier estimator and univariate and multivariate Cox proportional hazard analyses were perfor…

Oncologymedicine.medical_specialtyLungBlood based biomarkersbusiness.industrySettore MED/06 - Oncologia Medicasmall-cell lung cancer (SCLC)systemic inflammatory responselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensInflammatory biomarkerslcsh:RC254-282Neuroendocrine Carcinomasmedicine.anatomical_structureOncologyInternal medicinemedicinePrognostic biomarkerNeuroendocrine carcinomaOriginal Articlebusinesspredictive biomarkerprognostic biomarkerneuroendocrine tumorPredictive biomarkerblood-based biomarker
researchProduct

Prognostic role in common clinical practice of neutrophil-to-lymphocyte ratio in unselected bladder cancer

2020

Oncologymedicine.medical_specialtyNo parole chiaveBladder cancerbusiness.industryUrologylcsh:Diseases of the genitourinary system. Urologylcsh:RC870-923lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaselcsh:RC254-282Clinical PracticeInternal medicinemedicineNeutrophil to lymphocyte ratiobusinessEuropean Urology Open Science
researchProduct

Secretory breast carcinoma with metastatic sentinel lymph node

2006

Abstract Background Secretory mammary carcinoma is a rare breast neoplasia originally described in children but sometimes also found in adults. It presents a more favourable outcome than more common histological types of breast carcinoma; published literature in fact reports only a few cases with axillary lymph node metastases and only four cases with distant metastases. Clinical presentation In this paper we report a rare case of secretory breast carcinoma with axillary lymph node metastases in a 33-year-old woman. To our knowledge, this is the first case of secretory carcinoma involving biopsy of the sentinel lymph node and investigation of the e-cadherin expression. We found positivity f…

Oncologymedicine.medical_specialtyPathologySentinel lymph nodelcsh:SurgeryCase ReportSettore MED/08 - Anatomia Patologicalcsh:RC254-282Mammary carcinomasentinel lymph nodeSurgical oncologyInternal medicinemedicineLymph nodebusiness.industrylcsh:RD1-811lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseSecretory breast carcinomaSettore MED/18 - Chirurgia GeneraleLymphedemamedicine.anatomical_structureSecretory breast carcinoma; sentinel lymph node; metastases; e-cadherinOncologymetastaseSurgerybusinessBreast carcinomae-cadherinSecretory Breast CarcinomaWorld Journal of Surgical Oncology
researchProduct

Transarterial radioembolization for hepatocellular carcinoma: a review

2016

Rodolfo Sacco,1 Caterina Conte,2 Emanuele Tumino,1 Giuseppe Parisi,1 Sara Marceglia,3 Salvatore Metrangolo,1 Roberto Eggenhoffner,4 Giampaolo Bresci,1 Giuseppe Cabibbo,5 Luca Giacomelli4 1Department of Gastroenterology, Cisanello Hospital, Pisa, 2Endocrinology and Metabolic Diseases, Policlinico A. Gemelli, Università Cattolica del Sacro Cuore, Rome, 3Department of Engineering and Architecture, University of Trieste, Trieste, 4Department of Surgical Sciences and Integrated Diagnostics, School of Medicine, Genova University, Genoa, 5Section of Gastroenterology, DIBIMIS, University of Palermo, Palermo, Italy Abstract: Hepatocellular carcinoma (HCC) is the most common type of liver canc…

Oncologymedicine.medical_specialtyReviewTransarterial RadioembolizationMalignancylcsh:RC254-28203 medical and health sciences0302 clinical medicineInternal medicineMedicineTherapeutic strategyCause of deathbusiness.industryTreatment optionshepatocellular carcinomahepatocellular carcinoma; transarterial radioembolizationmedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensdigestive system diseasesSafety profile030220 oncology & carcinogenesisHepatocellular carcinomatransarterial radioembolization030211 gastroenterology & hepatologybusinessLiver cancerhepatocellular carcinoma transarterial radioembolization
researchProduct